COVID-19 mRNA vaccine in patients with lymphoid malignancy or anti-CD20 antibody therapy: a systematic review and meta-analysis

Y Ito, A Honda, M Kurokawa - Clinical Lymphoma Myeloma and Leukemia, 2022 - Elsevier
Background The humoral response to vaccination in individuals with lymphoid malignancies
or those undergoing anti-CD20 antibody therapy is impaired, but details of the response to …

[HTML][HTML] Immune response to COVID-19 vaccination in a population with and without a previous SARS-CoV-2 infection

M Duro, C Almeida, I Duro, A Sarmento - Irish Journal of Medical Science …, 2023 - Springer
Abstract Purpose To evaluate IgG production in a group of vaccinated and unvaccinated
subjects previously infected, or not, with SARS-CoV-2. Methods A total of 316 subjects were …

[HTML][HTML] Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer

N Bordry, A Addeo, C Jaksic, V Dutoit… - Iscience, 2022 - cell.com
Little is known on the long-lasting humoral response and the T cell activation induced by
SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the …

Humoral and cellular responses to mRNA vaccines against SARS-CoV2 in patients with a history of CD20-B-cell depleting therapy

MB Moor, F Suter-Riniker, MP Horn, D Aeberli… - medRxiv, 2021 - medrxiv.org
Background B-cell depleting therapies increase COVID19 morbidity and mortality. For this
specific population, evidence-based vaccination strategies are lacking. Here, we …

[PDF][PDF] EFECTIVIDAD DE VACUNACIÓN COVID-19 EN PACIENTES ONCOLÓGICOS VACUNADOS VERSUS NO VACUNADOS

RR GAMARRA, AI MACHICAO, ÓE ANDRADE… - revista.oncologia.org.ve
RESUMEN OBJETIVO: La vacunación en pacientes oncológicos no tiene tanta efectividad
comparada a sanos. Nuestro objetivo fue investigar la efectividad de 5 tipos de vacuna …